RT @GoggleDocs: 9) Although it other mechanisms include ⤵️ Glucose ⤵️ Weight ⤵️ BP ⤵️ Inflammation ⤵️ fibrosis at described by @Thoma…
RT @GoggleDocs: 9) Although it other mechanisms include ⤵️ Glucose ⤵️ Weight ⤵️ BP ⤵️ Inflammation ⤵️ fibrosis at described by @Thoma…
RT @GoggleDocs: 9) Although it other mechanisms include ⤵️ Glucose ⤵️ Weight ⤵️ BP ⤵️ Inflammation ⤵️ fibrosis at described by @Thoma…
9) Although it other mechanisms include ⤵️ Glucose ⤵️ Weight ⤵️ BP ⤵️ Inflammation ⤵️ fibrosis at described by @ThomasZelniker 🔗https://t.co/6SfPwxE4we https://t.co/AQP3usgPVt
RT @MCW_Nephrology: Mechanistic overview of Sodium-Glucose Cotransporter 2 Inhibitor #cardiorenal Protection 🔗 https://t.co/LDSUA2mJJW #Nep…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
RT @edgarvlermamd: Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi shoul…
Treating patients with multiple comorbidities with CKD from @sankarnava 📌 Lifestyle modification is vital 📌 RASi should be optimized 📌 SGLT2i is recommended for eGFR>20 📌 Consider statins #NKFClinicals #Nephpearls 👉🏼 https://t.co/y3nV331wjm 👉🏼 ht
RT @MCW_Nephrology: Mechanistic overview of Sodium-Glucose Cotransporter 2 Inhibitor #cardiorenal Protection 🔗 https://t.co/LDSUA2mJJW #Nep…
RT @MCW_Nephrology: Mechanistic overview of Sodium-Glucose Cotransporter 2 Inhibitor #cardiorenal Protection 🔗 https://t.co/LDSUA2mJJW #Nep…
RT @MCW_Nephrology: Mechanistic overview of Sodium-Glucose Cotransporter 2 Inhibitor #cardiorenal Protection 🔗 https://t.co/LDSUA2mJJW #Nep…
RT @MCW_Nephrology: Mechanistic overview of Sodium-Glucose Cotransporter 2 Inhibitor #cardiorenal Protection 🔗 https://t.co/LDSUA2mJJW #Nep…
RT @MCW_Nephrology: Mechanistic overview of Sodium-Glucose Cotransporter 2 Inhibitor #cardiorenal Protection 🔗 https://t.co/LDSUA2mJJW #Nep…
RT @MCW_Nephrology: Mechanistic overview of Sodium-Glucose Cotransporter 2 Inhibitor #cardiorenal Protection 🔗 https://t.co/LDSUA2mJJW #Nep…
RT @MCW_Nephrology: Mechanistic overview of Sodium-Glucose Cotransporter 2 Inhibitor #cardiorenal Protection 🔗 https://t.co/LDSUA2mJJW #Nep…
RT @MCW_Nephrology: Mechanistic overview of Sodium-Glucose Cotransporter 2 Inhibitor #cardiorenal Protection 🔗 https://t.co/LDSUA2mJJW #Nep…
RT @MCW_Nephrology: Mechanistic overview of Sodium-Glucose Cotransporter 2 Inhibitor #cardiorenal Protection 🔗 https://t.co/LDSUA2mJJW #Nep…
RT @MCW_Nephrology: Mechanistic overview of Sodium-Glucose Cotransporter 2 Inhibitor #cardiorenal Protection 🔗 https://t.co/LDSUA2mJJW #Nep…
RT @MCW_Nephrology: Mechanistic overview of Sodium-Glucose Cotransporter 2 Inhibitor #cardiorenal Protection 🔗 https://t.co/LDSUA2mJJW #Nep…
RT @MCW_Nephrology: Mechanistic overview of Sodium-Glucose Cotransporter 2 Inhibitor #cardiorenal Protection 🔗 https://t.co/LDSUA2mJJW #Nep…
RT @MCW_Nephrology: Mechanistic overview of Sodium-Glucose Cotransporter 2 Inhibitor #cardiorenal Protection 🔗 https://t.co/LDSUA2mJJW #Nep…
RT @MCW_Nephrology: Mechanistic overview of Sodium-Glucose Cotransporter 2 Inhibitor #cardiorenal Protection 🔗 https://t.co/LDSUA2mJJW #Nep…
RT @MCW_Nephrology: Mechanistic overview of Sodium-Glucose Cotransporter 2 Inhibitor #cardiorenal Protection 🔗 https://t.co/LDSUA2mJJW #Nep…
RT @MCW_Nephrology: Mechanistic overview of Sodium-Glucose Cotransporter 2 Inhibitor #cardiorenal Protection 🔗 https://t.co/LDSUA2mJJW #Nep…
RT @MCW_Nephrology: Mechanistic overview of Sodium-Glucose Cotransporter 2 Inhibitor #cardiorenal Protection 🔗 https://t.co/LDSUA2mJJW #Nep…
RT @MCW_Nephrology: Mechanistic overview of Sodium-Glucose Cotransporter 2 Inhibitor #cardiorenal Protection 🔗 https://t.co/LDSUA2mJJW #Nep…
Mechanistic overview of Sodium-Glucose Cotransporter 2 Inhibitor #cardiorenal Protection 🔗 https://t.co/LDSUA2mJJW #Nephrology #SGLT2 #MedEd https://t.co/7LS5WR734c
【S22-5】SGLT2阻害薬の心腎効果のメカニズム https://t.co/C2h6AJeKxD #jsphcs2021
RT @cardiomet_CE: 17) . . . Check out this #StateoftheArt review in @JACCJournals #OpenAccess by @ZelnikerThomas & #ProfBraunwald https://…
RT @cardiomet_CE: 17) . . . Check out this #StateoftheArt review in @JACCJournals #OpenAccess by @ZelnikerThomas & #ProfBraunwald https://…
RT @cardiomet_CE: 17) . . . Check out this #StateoftheArt review in @JACCJournals #OpenAccess by @ZelnikerThomas & #ProfBraunwald https://…
RT @cardiomet_CE: 17) . . . Check out this #StateoftheArt review in @JACCJournals #OpenAccess by @ZelnikerThomas & #ProfBraunwald https://…
17) . . . Check out this #StateoftheArt review in @JACCJournals #OpenAccess by @ZelnikerThomas & #ProfBraunwald https://t.co/O87PLZXLwm https://t.co/vzF5VLMcJs
RT @JACCJournals: Are you familiar with the cardio-metabolic-renal benefits of #SGLT2I? Drs. @ZelnikerThomas and Eugene Braunwald summarize…
RT @CardioNerds: Now @CarineHamo @hopkinsheart teaching about the various SGLT2/1i! Terrific review: https://t.co/vXUytjfwXV
RT @CardioNerds: Now @CarineHamo @hopkinsheart teaching about the various SGLT2/1i! Terrific review: https://t.co/vXUytjfwXV
Now @CarineHamo @hopkinsheart teaching about the various SGLT2/1i! Terrific review: https://t.co/vXUytjfwXV
RT @AimanSmer: Who should prescribe SGLT2i to Heart Failure patients and why ? #cardiotwitter #MedTwitter #heartfailure #Cardiology #diab…
RT @AimanSmer: Who should prescribe SGLT2i to Heart Failure patients and why ? #cardiotwitter #MedTwitter #heartfailure #Cardiology #diab…
Who should prescribe SGLT2i to Heart Failure patients and why ? #cardiotwitter #MedTwitter #heartfailure #Cardiology #diabetes @ACPinternists @NMHheartdoc @gcfmd @coconnormd @AndrewJSauer @EiranGorodeski @SelmaFMohammed @DrNancySweitzer @DLBHATTMD https
RT @KardiologieWien: @ZelnikerThomas, joining us at @MedUni_Wien after spending several years @TIMIStudyGroup and Dr. Eugene Braunwald prov…
RT @KardiologieWien: @ZelnikerThomas, joining us at @MedUni_Wien after spending several years @TIMIStudyGroup and Dr. Eugene Braunwald prov…
RT @KardiologieWien: @ZelnikerThomas, joining us at @MedUni_Wien after spending several years @TIMIStudyGroup and Dr. Eugene Braunwald prov…
RT @KardiologieWien: @ZelnikerThomas, joining us at @MedUni_Wien after spending several years @TIMIStudyGroup and Dr. Eugene Braunwald prov…
RT @KardiologieWien: @ZelnikerThomas, joining us at @MedUni_Wien after spending several years @TIMIStudyGroup and Dr. Eugene Braunwald prov…
RT @KardiologieWien: @ZelnikerThomas, joining us at @MedUni_Wien after spending several years @TIMIStudyGroup and Dr. Eugene Braunwald prov…
RT @KardiologieWien: @ZelnikerThomas, joining us at @MedUni_Wien after spending several years @TIMIStudyGroup and Dr. Eugene Braunwald prov…
@ZelnikerThomas, joining us at @MedUni_Wien after spending several years @TIMIStudyGroup and Dr. Eugene Braunwald provide an overview of the cardio-metabolic-renal benefits of SGLT2i in @JACCJournals Part 1: https://t.co/kGeyh7Kz6L Part 2: https://t.co/
RT @sociedadSEEN: Mecanismos de los efectos #cardiorrenales de los #ISGLT2 Esta revisión proporciona un panorama general de la comprensión…
RT @sociedadSEEN: Mecanismos de los efectos #cardiorrenales de los #ISGLT2 Esta revisión proporciona un panorama general de la comprensión…
RT @sociedadSEEN: Mecanismos de los efectos #cardiorrenales de los #ISGLT2 Esta revisión proporciona un panorama general de la comprensión…
RT @sociedadSEEN: Mecanismos de los efectos #cardiorrenales de los #ISGLT2 Esta revisión proporciona un panorama general de la comprensión…
RT @JACCJournals: Are you familiar with the cardio-metabolic-renal benefits of #SGLT2I? Drs. @ZelnikerThomas and Eugene Braunwald summarize…
RT @sociedadSEEN: Mecanismos de los efectos #cardiorrenales de los #ISGLT2 Esta revisión proporciona un panorama general de la comprensión…
RT @sociedadSEEN: Mecanismos de los efectos #cardiorrenales de los #ISGLT2 Esta revisión proporciona un panorama general de la comprensión…
Mecanismos de los efectos #cardiorrenales de los #ISGLT2 Esta revisión proporciona un panorama general de la comprensión actual de los mecanismos de los beneficios cardio-metabólicos-renales de los iSGLT2 y resume los ensayos clínicos recientes con iSGLT2:
RT @academiamir: Los SGLT2i, un nuevo tipo de antidiabético, han demostrado mejorar el perfil metabólico, reducir la aterosclerosis y la pr…
RT @academiamir: Los SGLT2i, un nuevo tipo de antidiabético, han demostrado mejorar el perfil metabólico, reducir la aterosclerosis y la pr…
RT @academiamir: Los SGLT2i, un nuevo tipo de antidiabético, han demostrado mejorar el perfil metabólico, reducir la aterosclerosis y la pr…